Kathie Bishop, PhD
Chief Scientific Officer
Kathie M. Bishop, Ph.D. joined Locana in August 2019 as Chief Scientific Officer. Dr. Bishop has 20 years experience in leading translational research and drug development, with a focus on novel therapeutics in neurological and rare diseases. She was previously CSO at Otonomy, where she led preclinical and clinical development of a pipeline of neurotology programs. Before that, she was CSO of Tioga Pharmaceuticals. From 2009 to 2015, Dr. Bishop served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translation and development of multiple programs in the neurology franchise including leading the development and clinical trials for SPINRAZA™ (nusinersen), the first approved treatment for patients with spinal muscular atrophy, Dr. Bishop also served in research and development leadership roles from to 2001 to 2009 at Ceregene, a company focused on the development of AAV-based gene therapy products for the treatment of neurodegenerative disorders. She conducted post-doctoral work at the Salk Institute for Biological Studies and obtained a Ph.D. in Neuroscience from the University of Alberta.